Japan Approves Shionogi Allergy Drug For Helping Unborns Breathe
This article was originally published in PharmAsia News
Executive Summary
Japan's health ministry agreed to cover Shionogi's betamethasone under the nation's health-insurance system. The drug has been sold in Japan since the 1960s, but only for treatment of allergies. The newly approved indication is for unborn babies to help them breathe. The approval marks the first in Japan for a treatment aimed at the not-yet-born. Shionogi markets the drug in Japan as Rinderon. (Click here for more